Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination product or experimental intervention consisting of three components: - "Comparator 3" (identity unspecified; likely a code name for an investigational or control substance in a clinical trial), - Alcohol (ethanol, a central nervous system depressant with sedative effects), - Energy drink (a beverage typically containing high levels of caffeine, sugar, taurine, B vitamins, and other stimulants). The combination of alcohol with energy drinks is well-documented to have unique pharmacological and behavioral effects compared to either component alone. Caffeine and other stimulants in the energy drink can mask the sedative effects of alcohol without reducing actual impairment. This leads to decreased perception of intoxication while increasing stimulation and desire to continue drinking. The result is often increased total alcohol consumption, higher risk behaviors (such as binge drinking), impaired judgment, greater risk for injury or accidents, dehydration, cardiovascular complications (elevated blood pressure/heart rate), arrhythmias, sleep disturbances, increased risk for addiction/dependence on both substances due to synergistic neurochemical interactions affecting dopamine pathways[1][2][4][5][7]. The specific mechanism by which this combination acts involves: - Alcohol potentiating GABAergic neurotransmission while inhibiting glutamatergic transmission, - Caffeine antagonizing adenosine receptors leading to increased alertness, - Potential modulation of dopamine release in reward pathways. This combination has been associated with public health concerns including increased rates of binge drinking among young people[1], higher incidence of risky sexual behavior[1], impaired driving[2], cardiovascular events[3][7], addiction potential[4][7], dehydration[2], sleep disruption[3] and even regulatory action against pre-mixed alcoholic energy drinks in some jurisdictions due to safety concerns[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Comparator 3 + alcohol + energy drink.